Interestingly, no significant reduction was noted in CD4+ T cells, CD8+ T cells or B cells, and an increase in the anti-tumor activity of CD8+ T cells and activated NK cells was noted, making this a promising MDSC targeting agent. This evidence concerns the gene CD8A and neoplasm.